AbCellera Biologics Inc. ABCL Cash, Cash Equivalents, and Marketable Securities
Cash, Cash Equivalents, and Marketable Securities at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecurities.
The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s cash, cash equivalents, and marketable securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s cash, cash equivalents, and marketable securities?
- AbCellera Biologics Inc. (ABCL) reported cash, cash equivalents, and marketable securities of $427.67M in Q1 2026.
- How has AbCellera Biologics Inc.'s cash, cash equivalents, and marketable securities changed year-over-year?
- AbCellera Biologics Inc.'s cash, cash equivalents, and marketable securities decreased by 4.1% year-over-year, from $446M to $427.67M.
- What is the long-term trend for AbCellera Biologics Inc.'s cash, cash equivalents, and marketable securities?
- Over 4 years (2021 to 2025), AbCellera Biologics Inc.'s cash, cash equivalents, and marketable securities has grown at a 13.2% compound annual growth rate (CAGR), from $246.84M to $405.31M.
- What does cash, cash equivalents, and marketable securities mean?
- This represents the most liquid assets held by the company, including cash on hand, bank deposits, and short-term investments that can be readily converted into cash. It serves as the primary buffer for operational liquidity and potential capital allocation activities. Investors monitor this to assess the company's ability to meet short-term obligations and fund growth initiatives.